13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001802630
Total reported value
$2.9B
$2.9B
93 檔
27.9%
The Q1 2026 SEC filing reveals that Soleus Capital Management, L.P. held a total portfolio value of $2.9B, covering 93 public equity positions.
Soleus Capital Management, L.P. executed strategic sector rebalancing during Q1 2026, establishing 25 new positions while fully exiting 27 holdings and trimming 30 positions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 12.06% | -0.03% | +22.53% | |
| 2 | CELC | Celcuity Inc | Stock-Other | 5.94% | +0.20% | -28.97% | |
| 3 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 5.42% | +0.12% | +28.35% | |
| 4 | PODD | Insulet CORP | Stock-Healthcare | 4.78% | +0.72% | +275.00% | |
| 5 | NVCR | NovoCure Limited | Stock-Healthcare | 4.63% | +0.55% | +23.00% | |
| 6 | UTHR | United Therapeutics CORP | Stock-Healthcare | 4.50% | -0.29% | +211.98% | |
| 7 | PRAX | Praxis Precision Medicines I | Stock-Other | 4.31% | -2.26% | -8.94% | |
| 8 | VCEL | Vericel CORP | Stock-Other | 3.32% | -1.08% | +233.65% | |
| 9 | ALKS | Alkermes plc | Stock-Healthcare | 2.82% | -0.96% | +49.04% | |
| 10 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 2.55% | -0.07% | +68.69% | |
| 11 | GMED | Globus Medical Inc - A | Stock-Healthcare | 2.55% | -1.27% | -17.76% | |
| 12 | GERN | Geron CORP | Stock-Other | 2.50% | -0.61% | +78.23% | |
| 13 | TWST | Twist Bioscience CORP | Stock-Other | 2.36% | -1.99% | -34.12% | |
| 14 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.85% | -1.22% | +59.33% | |
| 15 | BBNX | Beta Bionics Inc | Stock-Other | 1.77% | +0.60% | +71.80% | |
| 16 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.76% | -1.42% | +88.07% | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.63% | -0.40% | -23.15% | |
| 18 | INDV | Indivior Pharmaceuticals Inc | Stock-Other | 1.57% | -0.07% | — | |
| 19 | NPCE | Neuropace Inc | Stock-Other | 1.56% | +0.03% | +8.47% | |
| 20 | LIVN | LivaNova PLC | Stock-Other | 1.50% | -0.78% | +2.64% | |
| 21 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.50% | -1.20% | -30.21% | |
| 22 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 1.49% | -0.75% | -50.71% | |
| 23 | PGNY | Progyny Inc | Stock-Other | 1.42% | +0.17% | — | |
| 24 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.20% | +1.77% | +92.49% | |
| 25 | FOCL | Edap Tms SA -adr | Stock-Other | 1.10% | +0.20% | — | |
| 26 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 1.02% | -0.48% | -11.18% | |
| 27 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.99% | -0.77% | — | |
| 28 | ORGO | Organogenesis Holdings Inc | Stock-Other | 0.97% | -0.12% | +1.00% | |
| 29 | NTRA | Natera Inc | Stock-Healthcare | 0.96% | -0.95% | +495.00% | |
| 30 | AXGN | Axogen Inc | Stock-Other | 0.91% | -0.82% | -43.72% | |
| 31 | PCVX | Vaxcyte Inc | Stock-Other | 0.91% | -0.91% | EXIT | |
| 32 | ICLR | ICON Public Limited Company | Stock-Healthcare | 0.86% | -0.86% | EXIT | |
| 33 | PHVS | Pharvaris N.V. | Stock-Other | 0.80% | +0.07% | — | |
| 34 | CERS | Cerus CORP | Stock-Other | 0.79% | -0.54% | +168.84% | |
| 35 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.78% | -0.02% | +80.00% | |
| 36 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.74% | +0.02% | — | |
| 37 | CNTX | Context Therapeutics Inc | Stock-Other | 0.74% | -0.61% | — | |
| 38 | VIR | Vir Biotechnology Inc | Stock-Other | 0.73% | -0.38% | — | |
| 39 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 0.69% | -0.13% | — | |
| 40 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.66% | -0.66% | EXIT | |
| 41 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 0.61% | -0.31% | — | |
| 42 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.59% | +0.63% | -23.06% | |
| 43 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.53% | +0.52% | +384.67% | |
| 44 | SION | Sionna Therapeutics Inc | Stock-Other | 0.48% | -0.21% | +9.31% | |
| 45 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 0.47% | -0.41% | — | |
| 46 | JBIO | Jade Biosciences Inc | Stock-Other | 0.45% | +0.74% | — | |
| 47 | VCYT | Veracyte Inc | Stock-Other | 0.42% | -0.37% | +3099.12% | |
| 48 | IVVD | Invivyd Inc | Stock-Other | 0.41% | -0.18% | — | |
| 49 | CCCC | C4 Therapeutics Inc | Stock-Other | 0.41% | +0.13% | — | |
| 50 | KIDS | Orthopediatrics CORP | Stock-Other | 0.40% | +0.08% | +17.13% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KRYS | Krystal Biotech Inc | +3.5% | +22.53% | Add |
| 2 | UTHR | United Therapeutics CORP | +3.4% | +211.98% | Add |
| 3 | PODD | Insulet CORP | +3.2% | +275.00% | Add |
| 4 | VCEL | Vericel CORP | +2.3% | +233.65% | Add |
| 5 | TGTX | Tg Therapeutics Inc | +2% | +28.35% | Add |
| 6 | ALKS | Alkermes plc | +1.5% | +49.04% | Add |
| 7 | GERN | Geron CORP | +1.4% | +78.23% | Add |
| 8 | ANIP | Ani Pharmaceuticals Inc | +1.1% | +68.69% | Add |
| 9 | EWTX | Edgewise Therapeutics Inc | +1% | +59.33% | Add |
| 10 | NTRA | Natera Inc | +0.8% | +495.00% | Add |
| 11 | ALNY | Alnylam Pharmaceuticals Inc | +0.7% | +88.07% | Add |
| 12 | NVCR | NovoCure Limited | +0.6% | +23.00% | Add |
| 13 | CERS | Cerus CORP | +0.5% | +168.84% | Add |
| 14 | VCYT | Veracyte Inc | +0.4% | +3099.12% | Add |
| 15 | URGN | UroGen Pharma Ltd. | +0.4% | +384.67% | Add |
| 16 | TNGX | Tango Therapeutics Inc | +0.4% | +4400.00% | Add |
| 17 | TRVI | Trevi Therapeutics Inc | +0.4% | +80.00% | Add |
| 18 | PRAX | Praxis Precision Medicines I | +0.4% | -8.94% | Trim |
| 19 | INBX | Inhibrx Biosciences Inc | +0.3% | +424.00% | Add |
| 20 | FOCL | Edap Tms SA -adr | +0.2% | — | Unchanged |
| 21 | LIVN | LivaNova PLC | +0.2% | +2.64% | Add |
| 22 | INSP | Inspire Medical Systems Inc | +0.2% | +92.49% | Add |
| 23 | TWST | Twist Bioscience CORP | +0.2% | -34.12% | Trim |
| 24 | CCCC | C4 Therapeutics Inc | +0.1% | — | Unchanged |
| 25 | KNSA | Kiniksa Pharmaceuticals International, plc | +0.1% | -11.18% | Trim |
| 26 | EOLS | Evolus Inc | +0.1% | +109.85% | Add |
| 27 | PHVS | Pharvaris N.V. | +0.1% | — | Unchanged |
| 28 | SION | Sionna Therapeutics Inc | +0.1% | +9.31% | Add |
| 29 | KIDS | Orthopediatrics CORP | +0.1% | +17.13% | Add |
| 30 | NPCE | Neuropace Inc | 0% | +8.47% | Add |
| 31 | QNRX | Quoin Pharmaceuticals Lt-adr | 0% | +190.92% | Add |
| 32 | JBIO | Jade Biosciences Inc | — | — | Unchanged |
| 33 | STAA | Staar Surgical Co | — | -20.00% | Trim |
| 34 | JSPR | Jasper Therapeutics Inc | — | +38.16% | Add |
| 35 | LBRX | Lb Pharmaceuticals Inc | — | — | Unchanged |
| 36 | NSPR | Inspiremd Inc | 0% | -9.07% | Trim |
| 37 | LUNG | Pulmonx CORP | 0% | +36.80% | Add |
| 38 | KPTI | Karyopharm Therapeutics Inc | 0% | — | Unchanged |
| 39 | AVTX | Avalo Therapeutics Inc | 0% | — | Unchanged |
| 40 | GPCR | Structure Therapeutics Inc | -0.1% | -11.11% | Trim |
| 41 | IKT | Inhibikase Therapeutics Inc | -0.1% | — | Unchanged |
| 42 | ZYME | Zymeworks Inc | -0.1% | -90.00% | Trim |
| 43 | TYRA | Tyra Biosciences Inc | -0.1% | -92.00% | Trim |
| 44 | SNDX | Syndax Pharmaceuticals Inc | -0.1% | -23.15% | Trim |
| 45 | SEPN | Septerna Inc | -0.1% | -28.27% | Trim |
| 46 | PCVX | Vaxcyte Inc | -0.1% | -36.70% | Trim |
| 47 | COGT | Cogent Biosciences Inc | -0.1% | -91.67% | Trim |
| 48 | NEO | Neogenomics Inc | -0.1% | -59.06% | Trim |
| 49 | MIRM | Mirum Pharmaceuticals Inc | -0.2% | -30.21% | Trim |
| 50 | ORKA | Oruka Therapeutics Inc | -0.2% | -97.37% | Trim |
According to official SEC Form 13F filings, Soleus Capital Management, L.P. reported a total U.S. public equity portfolio value of $2.9B across 93 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including KRYS, CELC, TGTX) accounted for 27.9% of total reported equity market value during Q1 2026.
Top New Position Initiated
INDV
市值: $38.8M
Top Position Liquidated / Trimmed
XBI
前期市值: $353.6M
During Q1 2026, Soleus Capital Management, L.P.'s top holdings by market value included KRYS (12.1%)、CELC (5.9%)、TGTX (5.4%). The largest single position, KRYS, represented 12.1% of total portfolio value.
In Q1 2026, Soleus Capital Management, L.P. made 111 total portfolio adjustments, initiating 25 new buys, adding to 29 positions, trimming 30 holdings, and fully liquidating 27 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.